Scott Braithwaite, MD, MSc
NYU Langone Health - Tenured Professor of Medicine
NYU Langone Health - Director, Division of Comparative Effectiveness and Decision Science
NYU Langone Health - Director, Division of Comparative Effectiveness and Decision Science
Education
MD, Medicine, SUNY at Stony Brook School of MedicineMSc, Clinical Research, University of Pittsburgh
BS, Physics, Massachusetts Institute of Technology
Research Interests
Cost-effectiveness, Decision science BIO
R. Scott Braithwaite is a Tenured Professor, Chief of the Section on Value Effectiveness (SOLVE) and Director of the Division of Comparative Effectiveness at New York University School of Medicine-Department of Population Health. Dr. Braithwaite earned his MD from the State University of New York at Stonybrook and his MSc in Clinical Research from the University of Pittsburgh. Dr. Braithwaite also completed a fellowship in Clinical Decision Making at Tufts University and is a recipient of a prestigious Robert Wood Johnson Foundation Faculty Scholar award. He is an accomplished investigator in the field of decision science, quality and cost-effectiveness with an outstanding record of funding from the NIH and other extramural sources. As chief of SOLVE, he is dedicated to advancing a program of rigorous, policy-relevant research to optimize quality and value in healthcare, incorporating methods of decision science, comparative effectiveness and cost effectiveness. In addition to his focus on improving care for chronic illness domestically, he also continues his important international work on HIV treatment strategies in developing countries. Projects
Principal Investigator, Could Long-Acting Medications Facilitate “Ending AIDS by 2030” in Southern Africa? An Allocative Efficiency Analysis. Active
Principal Investigator, From 90-90-90 to 95-95-95 and Beyond: Optimizing and Targeting Combination HIV Prevention for Zimbabwe and Kwazulu Natal. Active
Principal Investigator, 4/6 COMPAAAS U01: Operations Research Study. Completed
Principal Investigator, Benefits and Harms of Lung Cancer Screening in HIV Infection. Completed
Principal Investigator, Implementation Science to Optimize HIV Prevention in East Africa PEPFAR Programs. Completed
Principal Investigator, Mentored Career Development in Comparative Effectiveness Research. Completed
Principal Investigator, Operations Research Collaboration for Alcohol Abuse and AIDS: ORCAAA. Completed
Principal Investigator, Reducing Morbidity and Mortality from Overdose, HIV, and Hepatitis C in Opioid-Using Persons. Completed
Publications
Recent
Khan MR, Acri M, Ban KF, Scheidell JD, Stevens ER, Manandhar-Sasaki P, Charles D, Chichetto NE, Crystal S, Gordon AJ, Marshall BDL, Edelman EJ, Justice AC, Braithwaite SR, Caniglia EC (2024).
Associations between reductions in depressive symptoms and reductions in pain and anxiety symptoms and substance use: Emulation of a randomized trial
AJPM Focus, 3 (5), 100258. doi: 10.1016/j.focus.2024.100258. PMCID: PMC11407062.
Associations between reductions in depressive symptoms and reductions in pain and anxiety symptoms and substance use: Emulation of a randomized trial
AJPM Focus, 3 (5), 100258. doi: 10.1016/j.focus.2024.100258. PMCID: PMC11407062.
Kaftan D, Kim HY, Ko C, Howard JS, Dalal P, Yamamoto N, Braithwaite RS, Bershteyn A (2024).
Performance analysis of mathematical methods used to forecast the 2022 New York City mpox outbreak
Journal of Medical Virology, 96 (8), e29791. doi: 10.1002/jmv.29791.
Performance analysis of mathematical methods used to forecast the 2022 New York City mpox outbreak
Journal of Medical Virology, 96 (8), e29791. doi: 10.1002/jmv.29791.
Ban KF, Rogers E, Khan M, Scheidell J, Charles D, Bryant KJ, Justice AC, Braithwaite RS, Caniglia EC (2024).
Does smoking cessation reduce other substance use, psychiatric symptoms, and pain symptoms? Results from an emulated hypothetical randomized trial of US veterans
PLoS One, 19 (7), e0298576. doi: 10.1371/journal.pone.0298576. PMCID: PMC11221691.
Does smoking cessation reduce other substance use, psychiatric symptoms, and pain symptoms? Results from an emulated hypothetical randomized trial of US veterans
PLoS One, 19 (7), e0298576. doi: 10.1371/journal.pone.0298576. PMCID: PMC11221691.
Feelemyer J, Braithwaite RS, Zhou Q, Cleland CM, Manandhar-Sasaki P, Wilton L, Ritchie A, Collins LM, Gwadz MV (2024).
Empirical development of a behavioral intervention for African American/Black and Latino persons with unsuppressed HIV viral load levels: An application of the Multiphase Optimization Strategy (MOST) using cost-effectiveness as an optimization objective
AIDS and Behavior, 28 (7), 2378-2390. doi: 10.1007/s10461-024-04335-w.
Empirical development of a behavioral intervention for African American/Black and Latino persons with unsuppressed HIV viral load levels: An application of the Multiphase Optimization Strategy (MOST) using cost-effectiveness as an optimization objective
AIDS and Behavior, 28 (7), 2378-2390. doi: 10.1007/s10461-024-04335-w.
Scheidell JD, Townsend TN, Zhou Q, Manandhar-Sasaki P, Rodriguez-Santana R, Jenkins M, Buchelli M, Charles DL, Frechette JM, Su JI, Braithwaite RS (2024).
Reducing overdose deaths among persons with opioid use disorder in Connecticut
Harm Reduction Journal, 21 (1), 103. doi: 10.1186/s12954-024-01026-6. PMCID: PMC11131266.
Dr. Braithwaite's ResearchGate Profile
Reducing overdose deaths among persons with opioid use disorder in Connecticut
Harm Reduction Journal, 21 (1), 103. doi: 10.1186/s12954-024-01026-6. PMCID: PMC11131266.